ELVN Latest Headlines

Enliven Therapeutics Raises $400 Million Through Upsized Public Offering: What Investors Should Know

Market Chameleon (Fri, 12-Jun 10:41 AM)

ELVN-001 Shows Promising Phase 1 Results, FDA Alignment Paves Way for Phase 3 ENABLE-2 Trial

Market Chameleon (Thu, 11-Jun 10:32 AM)

ELVN-001 Shows Robust Efficacy and Strong FDA Alignment for Phase 3 CML Trial—What Do the Numbers Reveal?

Market Chameleon (Thu, 11-Jun 9:04 AM)